NY State Senate Bill S5150B

Archive: Last Bill Status - Passed Senate

Introduced
In Committee
On Floor Calendar
- Passed Senate
- Passed Assembly
Delivered to Governor
Signed/Vetoed by Governor

Your Voice

Please enter your contact information

First Name *

Last Name *

Email Address *

A valid email address is required.

Home address search or enter your address manually *

Home address is used to determine the senate district in which you reside. Your support or opposition to this bill is then shared immediately with the senator who represents you.

Optional services from the NY State Senate:

Create an account. An account allows you to officially support or oppose key legislation, sign petitions with a single click, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.

Include a custom message for your Senator? (Optional)

Enter a message to your senator. Many New Yorkers use this to share the reasoning behind their support or opposition to the bill. Others might share a personal anecdote about how the bill would affect them or people they care about.

Leave this field blank

Actions

view actions (14)

	Assembly Actions - Lowercase Senate Actions - UPPERCASE
Feb 04, 2020	referred to ways and means delivered to assembly passed senate
Feb 03, 2020	ordered to third reading cal.331 committee discharged and committed to rules
Jan 08, 2020	referred to health
Jun 20, 2019	recommitted to rules
Jun 19, 2019	ordered to third reading cal.1773 committee discharged and committed to rules
Jun 13, 2019	print number 5150b
Jun 13, 2019	amend and recommit to health
May 22, 2019	print number 5150a
May 22, 2019	amend (t) and recommit to health
Apr 11, 2019	referred to health

Votes

view votes

Feb 4, 2020 - floor Vote

S5150B

floor

Aye

Nay

Absent

Excused

Abstained

Feb 3, 2020 - Rules committee Vote

S5150B

committee

Aye

Nay

Aye with Reservations

Absent

Excused

Abstained

Jun 19, 2019 - Rules committee Vote

S5150B

committee

Aye

Nay

Aye with Reservations

Absent

Excused

Abstained

Bill Amendments

Original

B (Active)

Original

B (Active)

Co-Sponsors

S5150 - Details

See Assembly Version of this Bill:: A5603
Law Section:: Public Health Law
Laws Affected:: Amd §3309, Pub Health L
Versions Introduced in 2021-2022 Legislative Session:: S2966, A336

S5150 - Summary

Provides that with the first opioid prescription of each year for use in a setting other than a general hospital or nursing home under article twenty-eight of this chapter or facility under article thirty-one of the mental hygiene law, or when a practitioner is prescribing a controlled substance to a patient under the care of hospice, the prescriber shall prescribe an opioid antagonist when any of the following risk factors are present: a history of substance abuse disorder; high dose or cumulative prescriptions that result in over 50 morphine milligram equivalents per day; concurrent use of opioids and benzodiazepine or nonbenzodiazepine sedative hypnotics.

S5150 - Sponsor Memo

 
BILL NUMBER: S5150

SPONSOR: HARCKHAM
 
TITLE OF BILL:  An act to amend the public health law, in relation to
prescribing an opioid antagonist with a patient's first opioid analgesic
prescription in a given year

 
PURPOSE OR GENERAL IDEA OF BILL:

To prescribe an opioid antagonist, a drug used to counter the effects of
opioid overdose, with a patient's first opioid analgesic prescription
each year.

 
SUMMARY OF SPECIFIC PROVISIONS:

Section 1. Adds a new subdivision 44 to Section 3302 of the public
health law. Subdivision 44 defines "opioid analgesics" as the medicines
buprenorphine, butorphanol, codeine, hydrocodone, hydromorphone, levor-
phanol, meperidine, methadone, morphine, nalbuphine, oxycodone, oxymor-
phone, pentazocine, propoxyphene, as well as their brand names, isomers
and combinations. This section also adds a new subdivision 45, which

defines an opioid antagonist as an FDA-approved drug that, when adminis-
tered, negates or neutralizes in whole or in part the pharmacological
effects of an opioid in the body. The opioid antagonist is limited to
naloxone or other medications approved by the department for this
purpose.

Section 2. Adds a new subdivision 7 to Section 3309 of the public health
law. Subdivision 7-a provides that every initial opioid analgesic
prescription per year shall be accompanied with a prescription for an
opioid antagonist if any of the following risk factors are present: a
history of substance use disorder; high does or cumulative prescriptions
that result in over fifty morphine milligram equivalents per day;
concurrent use of opioids and benzodiazepine or nonbenzodiazepine seda-
tive hypnotics.

Subdivision 7-b mandates that a prescriber who fails to prescribe a
prescription, as required by this subdivision, shall be referred to the
appropriate licensing board solely for the imposition of administrative
sanctions deemed appropriate by such board. This section shall not
create a private right of action against a prescriber.

Section 3. Contains the effective date.

 
JUSTIFICATION:

Drug poisoning is the leading cause of death from injuries in the United
States. In New York State and New York City, between 1999 and 2008 the
leading cause of accidental death was overdose, ahead of accidental
falls and motor vehicle accidents. The vast majority of these overdose
deaths occurred inside the home.

According to studies by the Centers for Disease Control and Prevention,
drug poisoning deaths involving opioid analgesics, also known as
prescription pain relievers, such as codeine and oxycodone, have more
than tripled nationally since 1999, and between 2000 and 2011, the rate
of drug poisoning deaths involving opioid analgesics in NYC increased by
267%. In 2012, prescription opioid analgesics were involved in 28% of
overdose deaths in NYC. Between 2015 and 2016 the opioid overdose death
rate in New York State increased by 40%. Additionally, eighty percent of
heroin users have reported that they used opioid analgesics before
switching to heroin. As of March 2018, more than 115 people in the
United States die every day from overdosing on opioids, according to the
CDC.

The CDC has stated that higher dosages of opioids are associated with
higher risks of overdosing. Furthermore, higher dosages have not been
shown to reduce pain over the long term. The CDC maintains the threshold
of "higher dosages" begins at 50 morphine milligram equivalents (MME)
per day, instructing clinicians to treat the prescription of 50 MME or
more as a risk factor for overdose. Dosages of 50 MME at least double
the risk of overdose from the risk at less than 20 MME.

Opioid antagonists, such as naloxone, are drugs that reverse the effects
of opioids, and are effective in preventing overdose deaths.  The avail-
ability of an opioid antagonist is crucial in ensuring that overdose
deaths do not occur. However, an opioid antagonist can only be effective
as an antidote if it is readily accessible when an overdose is happen-
ing. Additionally, opioid antagonists are non-habit forming and non-tox-
ic. On April 5th, 2018, the United States Surgeon General issued the
first national advisory in over a decade, urging all Americans to carry
naloxone.

Currently, opioid antagonists can only be used if they are prescribed.
A recent NYC Department of Mental Health and Hygiene study supported a
co-prescribing mandate to increase the availability of opioid antag-
onists. This legislation, by increasing access to opioid antagonists,
may be able to save the lives of those at risk for opioid analgesic
overdoses.

 
PRIOR LEGISLATIVE HISTORY:

2013-2014: A.9365 - Referred to Health.
2015-2016: A.661 - Referred to Health.
2017-2018: A.1531-A - Referred to Health.

 
FISCAL IMPLICATIONS:

None.

 
EFFECTIVE DATE:
This act shall take effect on the ninetieth day after it shall have
become a law. Effective immediately, the addition, amendment and/or
repeal of any rule or regulation necessary for the implementation of
this act on its effective date are authorized to be made and completed
by the commissioner of health on or before such effective date.

S5150 - Bill Text download pdf


                    S T A T E   O F   N E W   Y O R K
________________________________________________________________________

                                  5150

                       2019-2020 Regular Sessions

                            I N  S E N A T E

                             April 11, 2019
                               ___________

Introduced  by Sen. HARCKHAM -- read twice and ordered printed, and when
  printed to be committed to the Committee on Health

AN ACT to amend the public health law, in  relation  to  prescribing  an
  opioid antagonist with a patient's first opioid analgesic prescription
  in a given year

  THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
BLY, DO ENACT AS FOLLOWS:

  Section 1. Section 3302 of the public health law is amended by  adding
two new subdivisions 44 and 45 to read as follows:
  44. "OPIOID ANALGESICS" MEANS THE MEDICINES BUPRENOPHINE, BUTORPHANOL,
CODEINE, HYDROCODONE, HYDROMORPHONE, LEVORPHANOL, MEPERIDINE, METHADONE,
MORPHINE,  NALBUPHINE, OXYCODONE, OXYMORPHONE, PENTAZOCINE, PROPOXYPHENE
AS WELL AS THEIR BRAND NAMES, ISOMERS AND COMBINATIONS.
  45. "OPIOID ANTAGONIST" MEANS AN FDA-APPROVED DRUG THAT, WHEN ADMINIS-
TERED, NEGATES OR NEUTRALIZES IN WHOLE OR IN  PART  THE  PHARMACOLOGICAL
EFFECTS  OF  AN  OPIOID IN THE BODY. THE OPIOID ANTAGONIST IS LIMITED TO
NALOXONE OR OTHER  MEDICATIONS  APPROVED  BY  THE  DEPARTMENT  FOR  THIS
PURPOSE.
  §  2. Section 3309 of the public health law is amended by adding a new
subdivision 7 to read as follows:
  7. (A) WITH THE FIRST OPIOID ANALGESIC OF EACH  YEAR,  THE  PRESCRIBER
SHALL  PRESCRIBE  AN  OPIOID  ANTAGONIST  WHEN ANY OF THE FOLLOWING RISK
FACTORS ARE PRESENT: A HISTORY OF SUBSTANCE USE DISORDER; HIGH  DOSE  OR
CUMULATIVE  PRESCRIPTIONS  THAT  RESULT IN OVER FIFTY MORPHINE MILLIGRAM
EQUIVALENTS PER DAY; CONCURRENT USE OF  OPIOIDS  AND  BENZODIAZEPINE  OR
NONBENZODIAZEPINE SEDATIVE HYPNOTICS.
  (B)  A  PRESCRIBER  WHO  FAILS  TO  PRESCRIBE AN OPIOID ANTAGONIST, AS
REQUIRED BY THIS SUBDIVISION,  SHALL  BE  REFERRED  TO  THE  APPROPRIATE
LICENSING  BOARD  SOLELY  FOR THE IMPOSITION OF ADMINISTRATIVE SANCTIONS
DEEMED APPROPRIATE BY SUCH  BOARD.  THIS  SECTION  SHALL  NOT  CREATE  A
PRIVATE  RIGHT  OF  ACTION  AGAINST  A  PRESCRIBER, AND DOES NOT LIMIT A

 EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                      [ ] is old law to be omitted.

                                                           LBD01771-06-9

S. 5150                             2

PRESCRIBER'S LIABILITY FOR THE NEGLIGENT FAILURE TO DIAGNOSE OR TREAT  A
PATIENT.
  §  3.  This  act shall take effect on the ninetieth day after it shall
have become a law. Effective immediately, the addition, amendment and/or
repeal of any rule or regulation necessary  for  the  implementation  of
this  act  on its effective date are authorized to be made and completed
by the commissioner of health on or before such effective date.

Co-Sponsors

S5150A - Details

See Assembly Version of this Bill:: A5603
Law Section:: Public Health Law
Laws Affected:: Amd §3309, Pub Health L
Versions Introduced in 2021-2022 Legislative Session:: S2966, A336

S5150A - Summary

S5150A - Sponsor Memo

 
BILL NUMBER: S5150A

SPONSOR: HARCKHAM
 
TITLE OF BILL:  An act to amend the public health law, in relation to
prescribing an opioid antagonist with a patient's first opioid
prescription in a given year

 
PURPOSE:

To prescribe an opioid antagonist, a drug used to counter the effects of
opioid overdose, with a patient's first opioid analgesic prescription
each year.

 
SUMMARY OF PROVISIONS:

Section 1. Adds a new subdivision 7 to Section 3309 of the public health
law, which provides that the first opioid prescription to a particular
patient each year shall be accompanied with a prescription for an opioid
antagonist if any of the following risk factors are present: a history
of substance use disorder; high doses or cumulative prescriptions that
result in over fifty morphine milligram equivalents per day; concurrent

use of opioid and benzodiazepine or nonbenzodiazepine sedative hypnot-
ics.

Section 2. Contains the effective date.

 
JUSTIFICATION:

Drug poisoning is the leading cause of death from injuries in the United
States. In New York State and New York City, between 1999 and 2008 the
leading cause of accidental death was overdose, ahead of accidental
falls and motor vehicle accidents. The vast majority of these overdose
deaths occurred inside the home.

According to studies by the Centers for Disease Control and Prevention,
drug poisoning deaths involving opioid analgesics, also known as
prescription pain relievers, such as codeine and oxycodone, have more
than tripled nationally since 1999, and between 2000 and 2011, the rate
of drug poisoning deaths involving opioid analgesics in NYC increased by
267%. In 2012, prescription opioid analgesics were involved in 28% of
overdose deaths in NYC. Between 2015 and 2016 the opioid overdose death
rate in New York State increased by 40%/ Additionally, eighty percent of
heroin users have reported that they used opioid analgesics before
switching to heroin. As of March 2018, more than 115 people in the
United States die every day from overdosing on opioids, according to the
CDC.

The CDC has stated that higher dosages of opioids are associated with
higher risks of overdosing. Furthermore, higher dosages have not been
shown to reduce pain over the long term. The CDC maintains the threshold
of "higher dosages" begins at 50 morphine milligram equivalents (MME)
per day, instructing clinicians to treat the prescription of 50 MME or
more as a risk factor for overdose. Dosages of 50 MME at least double
the risk of overdose from the risk at less than 20 MME.

Opioid antagonists, such as naloxone, are drugs that reverse the effects
of opioids, and are effective in preventing overdose deaths.  The avail-
ability of an opioid antagonist is crucial in ensuring that overdose
deaths do not occur. However, an opioid antagonist can only be effective
as an antidote if it is readily accessible when an overdose is happen-
ing. Additionally, opioid antagonists are non-habit forming and non-tox-
ic. On April 5th, 2018, the United States Surgeon General issued the
first national advisory in over a decade, urging all Americans to carry
naloxone.

Currently, opioid antagonists can only be used if they are prescribed.
A recent NYC Department of Mental Health and Hygiene study supported a
co-prescribing mandate to increase the availability of opioid antag-
onists. This legislation, by increasing access to opioid antagonists,
may be able to save the lives of those at risk for opioid analgesic
overdoses.

 
LEGISLATIVE HISTORY:

2013-2014: A9365-Referred to Health
2015-2016: A661-Referred to Health
2017-2018: A1531-A- Referred to Health

 
FISCAL IMPLICATIONS:

None to the state.

 
EFFECTIVE DATE:
This act shall take effect on the one hundred eightieth day after it
shall have become a law. Effective immediately, the addition, amendment
and/or repeal of any rule or regulation necessary for the implementation
of this act on its effective date are authorized to be made and
completed by the commissioner of health on or before such effective
date.

S5150A - Bill Text download pdf


                    S T A T E   O F   N E W   Y O R K
________________________________________________________________________

                                 5150--A

                       2019-2020 Regular Sessions

                            I N  S E N A T E

                             April 11, 2019
                               ___________

Introduced by Sens. HARCKHAM, SALAZAR -- read twice and ordered printed,
  and when printed to be committed to the Committee on Health -- commit-
  tee  discharged, bill amended, ordered reprinted as amended and recom-
  mitted to said committee

AN ACT to amend the public health law, in  relation  to  prescribing  an
  opioid  antagonist  with  a  patient's  first opioid prescription in a
  given year

  THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND  ASSEM-
BLY, DO ENACT AS FOLLOWS:

  Section  1. Section 3309 of the public health law is amended by adding
a new subdivision 7 to read as follows:
  7. WITH THE FIRST PRESCRIPTION TO A PARTICULAR PATIENT OF AN OPIOID OF
EACH YEAR FOR USE IN A SETTING OTHER THAN A GENERAL HOSPITAL OR  NURSING
HOME  UNDER ARTICLE TWENTY-EIGHT OF THIS CHAPTER OR FACILITY UNDER ARTI-
CLE THIRTY-ONE OF THE MENTAL HYGIENE LAW, THE PRESCRIBER SHALL PRESCRIBE
AN OPIOID ANTAGONIST WHEN ANY OF THE FOLLOWING RISK FACTORS ARE PRESENT:
(A) A HISTORY OF SUBSTANCE USE DISORDER; (B)  HIGH  DOSE  OR  CUMULATIVE
PRESCRIPTIONS  THAT  RESULT IN OVER FIFTY MORPHINE MILLIGRAM EQUIVALENTS
PER DAY; (C) CONCURRENT USE OF OPIOIDS AND BENZODIAZEPINE  OR  NONBENZO-
DIAZEPINE SEDATIVE HYPNOTICS.
  § 2. This act shall take effect on the one hundred eightieth day after
it  shall have become a law. Effective immediately, the addition, amend-
ment and/or repeal of any rule or regulation necessary for the implemen-
tation of this act on its effective date are authorized to be  made  and
completed  by  the  commissioner  of  health on or before such effective
date.


 EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                      [ ] is old law to be omitted.
                                                           LBD01771-08-9

Co-Sponsors

S5150B (ACTIVE) - Details

See Assembly Version of this Bill:: A5603
Law Section:: Public Health Law
Laws Affected:: Amd §3309, Pub Health L
Versions Introduced in 2021-2022 Legislative Session:: S2966, A336

S5150B (ACTIVE) - Summary

S5150B (ACTIVE) - Sponsor Memo

 
BILL NUMBER: S5150B

SPONSOR: HARCKHAM
 
TITLE OF BILL:  An act to amend the public health law, in relation to
prescribing an opioid antagonist with a patient's first opioid
prescription in a given year

 
PURPOSE:

To prescribe an opioid antagonist, a drug used to counter the effects of
opioid overdose, with a patient's first opioid analgesic prescription
each year.

 
SUMMARY OF PROVISIONS:

Section 1. Adds a new subdivision 7 to Section 3309 of the public health
law, which provides that the first opioid prescription to a particular
patient each year, in a setting other than a general hospital, nursing
home, or hospice care, shall be accompanied with a prescription for an
opioid antagonist if any of the following risk factors are present: a
history of substance use disorder; high doses or cumulative

prescriptions that result in over fifty morphine milligram equivalents
per day; concurrent use of opioid and benzodiazepine or nonbenzodiaze-
pine sedative hypnotics.

Section 2. Contains the effective date.

 
JUSTIFICATION:

Drug poisoning is the leading cause of death from injuries in the United
States. In New York State and New York City, between 1999 and 2008 the
leading cause of accidental death was overdose, ahead of accidental
falls and motor vehicle accidents. The vast majority of these overdose
deaths occurred inside the home.

According to studies by the Centers for Disease Control and Prevention,
drug poisoning deaths involving opioid analgesics, also known as
prescription pain relievers, such as codeine and oxycodone, have more
than tripled nationally since 1999, and between 2000 and 2011, the rate
of drug poisoning deaths involving opioid analgesics in NYC increased by
267%. In 2012, prescription opioid analgesics were involved in 28% of
overdose deaths in NYC. Between 2015 and 2016 the opioid overdose death
rate in New York State increased by 40%/ Additionally, eighty percent of
heroin users have reported that they used opioid analgesics before
switching to heroin. As of March 2018, more than 115 people in the
United States die every day from overdosing on opioids, according to the
CDC.

The CDC has stated that higher dosages of opioids are associated with
higher risks of overdosing. Furthermore, higher dosages have not been
shown to reduce pain over the long term. The CDC maintains the threshold
of "higher dosages" begins at 50 morphine milligram equivalents (MME)
per day, instructing clinicians to treat the prescription of 50 MME or
more as a risk factor for overdose. Dosages of 50 MME at least double
the risk of overdose from the risk at less than 20 MME.

Opioid antagonists, such as naloxone, are drugs that reverse the effects
of opioids, and are effective in preventing overdose deaths.  The avail-
ability of an opioid antagonist is crucial in ensuring that overdose
deaths do not occur. However, an opioid antagonist can only be effective
as an antidote if it is readily accessible when an overdose is happen-
ing. Additionally, opioid antagonists are non-habit forming and non-tox-
ic. On April 5th, 2018, the United States Surgeon General issued the
first national advisory in over a decade, urging all Americans to carry
naloxone.

Currently, opioid antagonists can only be used if they are prescribed.
A recent NYC Department of Mental Health and Hygiene study supported a
co-prescribing mandate to increase the availability of opioid antag-
onists. This legislation, by increasing access to opioid antagonists,
may be able to save the lives of those at risk for opioid analgesic
overdoses.

 
LEGISLATIVE HISTORY:

2013-2014: A9365-Referred to Health
2015-2016: A661-Referred to Health
2017-2018: A1531-A- Referred to Health

 
FISCAL IMPLICATIONS:

None to the state.

 
EFFECTIVE DATE:
This act shall take effect on the one hundred eightieth day after it
shall have become a law. Effective immediately, the addition, amendment
and/or repeal of any rule or regulation necessary for the implementation
of this act on its effective date are authorized to be made and
completed by the commissioner of health on or before such effective
date.

S5150B (ACTIVE) - Bill Text download pdf


                    S T A T E   O F   N E W   Y O R K
________________________________________________________________________

                                 5150--B

                       2019-2020 Regular Sessions

                            I N  S E N A T E

                             April 11, 2019
                               ___________

Introduced  by  Sens.  HARCKHAM,  CARLUCCI,  SALAZAR  --  read twice and
  ordered printed, and when printed to be committed to the Committee  on
  Health  --  committee  discharged,  bill amended, ordered reprinted as
  amended and recommitted to said  committee  --  committee  discharged,
  bill  amended,  ordered  reprinted  as amended and recommitted to said
  committee

AN ACT to amend the public health law, in  relation  to  prescribing  an
  opioid  antagonist  with  a  patient's  first opioid prescription in a
  given year

  THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND  ASSEM-
BLY, DO ENACT AS FOLLOWS:

  Section  1. Section 3309 of the public health law is amended by adding
a new subdivision 7 to read as follows:
  7. WITH THE FIRST PRESCRIPTION TO A PARTICULAR PATIENT OF AN OPIOID OF
EACH YEAR FOR USE IN A SETTING OTHER THAN A GENERAL HOSPITAL OR  NURSING
HOME  UNDER ARTICLE TWENTY-EIGHT OF THIS CHAPTER OR FACILITY UNDER ARTI-
CLE THIRTY-ONE OF THE MENTAL HYGIENE LAW,  OR  WHEN  A  PRACTITIONER  IS
PRESCRIBING  A  CONTROLLED  SUBSTANCE  TO  A  PATIENT  UNDER THE CARE OF
HOSPICE AS DEFINED BY SECTION FOUR THOUSAND TWO  OF  THIS  CHAPTER,  THE
PRESCRIBER  SHALL PRESCRIBE AN OPIOID ANTAGONIST WHEN ANY OF THE FOLLOW-
ING RISK FACTORS ARE PRESENT: (A) A HISTORY OF SUBSTANCE  USE  DISORDER;
(B)  HIGH  DOSE  OR  CUMULATIVE  PRESCRIPTIONS THAT RESULT IN OVER FIFTY
MORPHINE MILLIGRAM EQUIVALENTS PER DAY; (C) CONCURRENT  USE  OF  OPIOIDS
AND BENZODIAZEPINE OR NONBENZODIAZEPINE SEDATIVE HYPNOTICS.
  § 2. This act shall take effect on the one hundred eightieth day after
it  shall have become a law. Effective immediately, the addition, amend-
ment and/or repeal of any rule or regulation necessary for the implemen-
tation of this act on its effective date are authorized to be  made  and
completed  by  the  commissioner  of  health on or before such effective
date.

 EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                      [ ] is old law to be omitted.
                                                           LBD01771-12-9

Comments

Open Legislation is a forum for New York State legislation. All comments are subject to review and community moderation is encouraged.

Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity, hate or toxic speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Attempts to intimidate and silence contributors or deliberately deceive the public, including excessive or extraneous posting/posts, or coordinated activity, are prohibited and may result in the temporary or permanent banning of the user. Comment moderation is generally performed Monday through Friday. By contributing or voting you agree to the Terms of Participation and verify you are over 13.

The New York State Senate

senate Bill S5150B

Sponsored By

Archive: Last Bill Status - Passed Senate

Your Voice

Actions

Votes

Feb 4, 2020 - floor Vote

Floor Vote: Feb 4, 2020

Feb 3, 2020 - Rules committee Vote

Rules Committee Vote: Feb 3, 2020

Jun 19, 2019 - Rules committee Vote

Rules Committee Vote: Jun 19, 2019

Bill Amendments

Co-Sponsors

S5150 - Details

S5150 - Summary

S5150 - Sponsor Memo

S5150 - Bill Text download pdf

Co-Sponsors

S5150A - Details

S5150A - Summary

S5150A - Sponsor Memo

S5150A - Bill Text download pdf

Co-Sponsors

S5150B (ACTIVE) - Details

S5150B (ACTIVE) - Summary

S5150B (ACTIVE) - Sponsor Memo

S5150B (ACTIVE) - Bill Text download pdf

Comments

senate Bill S5150B

Share this bill

Sponsored By

Archive: Last Bill Status - Passed Senate

Your Voice

Actions

Votes

Feb 4, 2020 - floor Vote

Floor Vote: Feb 4, 2020

Feb 3, 2020 - Rules committee Vote

Rules Committee Vote: Feb 3, 2020

Jun 19, 2019 - Rules committee Vote

Rules Committee Vote: Jun 19, 2019

Bill Amendments

Co-Sponsors

S5150 - Details

S5150 - Summary

S5150 - Sponsor Memo

S5150 - Bill Text download pdf

Co-Sponsors

S5150A - Details

S5150A - Summary

S5150A - Sponsor Memo

S5150A - Bill Text download pdf

Co-Sponsors

S5150B (ACTIVE) - Details

S5150B (ACTIVE) - Summary

S5150B (ACTIVE) - Sponsor Memo

S5150B (ACTIVE) - Bill Text download pdf

Comments